Is Adderall affected by genetics?

Yes — all 2 active ingredients have pharmacogenetic evidence.

Relevant genes: CYP2D6

Used for: ADHD, narcolepsy

Considering GeneSight for Adderall?

Gene2Rx covers this medication using the same CPIC and FDA guidelines GeneSight uses, costs $5-$49 instead of several hundred, and works with your existing 23andMe data.

See the comparison →

Adderall is a racemic mixture, a 3:1 ratio of d-amphetamine to l-amphetamine, and that mixture (not a single compound) is what defines its clinical profile. Both enantiomers clear through CYP2D6, the most pharmacogenetically variable drug-metabolizing enzyme in the human genome. That's why two people can take the same 20 mg Adderall dose and have very different experiences: same drug, different enzyme, different plasma curves. CYP2D6 poor metabolizers feel Adderall strongly and for longer than the label suggests. Ultrarapid metabolizers often feel it weakly or not at all, and are at higher risk of dose escalation when it seems to stop working.

What's in Adderall

amphetamine affected by CYP2D6

Affected by CYP2D6 · FDA · Moderate evidence

Amphetamine (the l-enantiomer in Adderall) is cleared primarily by CYP2D6, with minor contributions from other pathways. On its own, l-amphetamine has slightly more peripheral (cardiovascular) activity and slightly less central (focus-related) activity than d-amphetamine. That's why pure d-amphetamine products like Dexedrine feel different from Adderall even at matched amphetamine content.

Read the full amphetamine genetics guide →

dextroamphetamine affected by CYP2D6

Affected by CYP2D6 · FDA · Moderate evidence

Dextroamphetamine is the more potent enantiomer for ADHD symptom control and is what most people describe when they say Adderall "works." It clears via CYP2D6. Ultrarapid metabolizers may find that Adderall XR wears off before the afternoon. Poor metabolizers may find that standard IR doses last past dinner and interfere with sleep.

Read the full dextroamphetamine genetics guide →

Amphetamine phenotype recommendations

Published guidance from FDA on how amphetamine should be dosed or substituted based on your CYP2D6 phenotype.

Phenotype	What it means	Recommendation	Evidence
Ultrarapid Metabolizer CYP2D6	Your body processes amphetamine faster than most people, but there is no specific FDA guidance for your genotype. The standard dose is typically used.	FDA Initiate therapy with recommended starting dose.	—
Normal Metabolizer CYP2D6	Your body processes amphetamine at a normal rate. The standard dose should work as expected.	FDA Initiate therapy with recommended starting dose.	—
Intermediate Metabolizer CYP2D6	Your body processes amphetamine slightly slower than average, but there is no specific FDA guidance for your genotype. The standard dose is typically used.	FDA Initiate therapy with recommended starting dose.	—
Poor Metabolizer CYP2D6	Your body breaks down amphetamine much more slowly than normal, which may cause the drug to build up and increase your risk of side effects. A lower dose or a different medication may be needed.	FDA Consider a lower starting dose or an alternative medication due to increased risk of side effects.	Moderate
Indeterminate CYP2D6	The impact of your genotype on response to this drug is unknown	FDA Initiate therapy with recommended starting dose.	—
Not available CYP2D6	The impact of your genotype on response to this drug is unknown	FDA Initiate therapy with recommended starting dose.	—

Source: FDA

Dextroamphetamine phenotype recommendations

Published guidance from FDA on how dextroamphetamine should be dosed or substituted based on your CYP2D6 phenotype.

Phenotype	What it means	Recommendation	Evidence
Ultrarapid Metabolizer CYP2D6	Your body processes amphetamine faster than most people, but there is no specific FDA guidance for your genotype. The standard dose is typically used.	FDA Initiate therapy with recommended starting dose.	—
Normal Metabolizer CYP2D6	Your body processes amphetamine at a normal rate. The standard dose should work as expected.	FDA Initiate therapy with recommended starting dose.	—
Intermediate Metabolizer CYP2D6	Your body processes amphetamine slightly slower than average, but there is no specific FDA guidance for your genotype. The standard dose is typically used.	FDA Initiate therapy with recommended starting dose.	—
Poor Metabolizer CYP2D6	Your body breaks down amphetamine much more slowly than normal, which may cause the drug to build up and increase your risk of side effects. A lower dose or a different medication may be needed.	FDA Consider a lower starting dose or an alternative medication due to increased risk of side effects.	Moderate
Indeterminate CYP2D6	The impact of your genotype on response to this drug is unknown	FDA Initiate therapy with recommended starting dose.	—
Not available CYP2D6	The impact of your genotype on response to this drug is unknown	FDA Initiate therapy with recommended starting dose.	—

Source: FDA

The gene behind the guidance

CYP2D6 Cytochrome P450 2D6

CYP2D6 is the most clinically important pharmacogene. It metabolizes around a quarter of all prescription drugs, including many antidepressants, opioids, and stimulants. The gene is unusually variable: roughly 7 percent of people are poor metabolizers (they barely activate CYP2D6), and another 1 to 3 percent are ultrarapid metabolizers (their enzyme is overactive).

For most CYP2D6 drugs, poor metabolizers feel stronger effects and more side effects at standard doses, while ultrarapid metabolizers may feel almost nothing. For prodrugs like codeine, the relationship flips: poor metabolizers feel less effect because they can't activate the drug.

See all drugs affected by CYP2D6 →

What this means for you

If you're on Adderall and the dose seems to drift (working well some weeks, not others, or needing frequent adjustment), it's worth distinguishing between tolerance, which develops over time, and a CYP2D6 phenotype mismatch, which was there from the start. A CYP2D6 test is a one-time data point that's genuinely useful for this class of medication, and many psychiatrists will factor it into dosing if you share the result.

FAQ

Is Adderall XR metabolized differently from Adderall IR?

No. The active ingredients and the metabolism are identical. XR just releases the amphetamine over a longer period, so the plasma curve is smoother. CYP2D6 genetics affect both formulations the same way.

Does being a CYP2D6 poor metabolizer mean I shouldn't take Adderall?

No. It means you and your prescriber should pay closer attention to starting dose and watch for stronger-than-expected effects. Many poor metabolizers take Adderall successfully on lower-than-average doses. It's not a contraindication. It's useful context.

Why does Mydayis have a different duration than Adderall XR?

Mydayis and Adderall XR have the same active ingredients (mixed amphetamine salts) and go through the same CYP2D6 pathway. The difference is the release profile. Mydayis is designed to release across three phases, extending the duration to roughly 16 hours. Your CYP2D6 metabolizer status still shapes how much of the dose actually reaches steady-state.

Related medications

Find out how your genetics affect Adderall

This page describes the general pharmacogenetics. A Gene2Rx report analyzes your own DNA to tell you which metabolizer group you fall into, across every medication.

Get your report Look up another medication

Informational only — not medical advice. Pharmacogenetic guidance describes population-level patterns; your individual response depends on many factors. Never start, stop, or change a medication without talking to your prescribing clinician.